Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365078 | 0.83 | RAB9A (0.72) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL27887616 | 0.81 | RAB9A (0.41) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL4144275 | 0.79 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL225275 | 0.79 | ALDH1A1 (0.54) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL7799474 | 0.79 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL27780484 | 0.78 | KMT2A (0.62) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL28882453 | 0.78 | KMT2A (0.52) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL17147852 | 0.78 | ALDH1A1 (0.58) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL70575 | 0.78 | KMT2A (0.56) | KMT2AALDH1A1MEN1MAPTMAPK1 | |
| SCHEMBL163274 | 0.78 | KMT2A (0.53) | KMT2AALDH1A1MEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4532501-B1 | CRYSTALLINE 6,7-DIHYDRO-4-HYDROXY-7-ISOPROPYL-6-OXO-N-(3-(PIPERIDIN-1-YL)PROPYL)THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDE POTASSIUM SALT (PRX-3140) FOR PARTICLE DELIVERY SYSTEMS (PDS) | NANOPHARMACEUTICS INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3967714-B1 | VINYL ALCOHOL-AMINO ACID ESTER COPOLYMER, THEIR PREPARATION AND USES | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-07 | — | — | EP | claimed |
| EP-4532501-A1 | CRYSTALLINE 6,7-DIHYDRO-4-HYDROXY-7-ISOPROPYL-6-OXO-N-(3-(PIPERIDIN-1-YL)PROPYL)THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDE POTASSIUM SALT (PRX-3140) FOR PARTICLE DELIVERY SYSTEMS (PDS) | Nanopharmaceutics, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| CN-119080799-A | N-hydroxythienopyrimidine diketone derivative and preparation method and application thereof | 山东大学 | 2024-12-06 | — | — | CN | claimed |
| US-11993609-B2 | Compositions and methods for oral delivery of crystalline PRX-3140 potassium salt | Nanopharmaceutics, Inc. (US) | 2024-05-28 | — | — | US | claimed |
| US-20230391791-A1 | Compositions And Methods For Oral Delivery Of Crystalline PRX-3140 Potassium Salt | Nanopharmaceutics, Inc. (US) | 2023-12-07 | — | — | US | claimed |
| WO-2023235166-A1 | CRYSTALLINE 6,7-DIHYDRO-4-HYDROXY-7-ISOPROPYL-6-OXO-N-(3-(PIPERIDIN-1-YL)PROPYL)THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDE POTASSIUM SALT (PRX-3140) FOR PARTICLE DELIVERY SYSTEMS (PDS) | Nanopharmaceutics, Inc. (US) | 2023-12-07 | — | — | WO | claimed |
| CN-113336769-B | Thienopyrimidine ketone acyl sulfonamide derivative as well as preparation method and application thereof | 山东大学 | 2022-06-24 | — | — | CN | claimed |
| CN-113336769-A | Thienopyrimidone acylsulfonamide derivative and preparation method and application thereof | 山东大学 | 2021-09-03 | — | — | CN | claimed |
| CN-111763218-B | Thienopyrimidinone thioglycolic acid derivative and preparation method and application thereof | 山东大学 | 2021-05-28 | — | — | CN | claimed |
| CN-112028884-A | Novel organic compound and preparation method and application thereof | 广州瀚信通信科技股份有限公司 | 2020-12-04 | — | — | CN | claimed |
| CN-111763218-A | Thienopyrimidinone thioglycolic acid derivative and preparation method and application thereof | 山东大学 | 2020-10-13 | — | — | CN | claimed |
| CN-109053712-A | A kind of 2- aminothiophene -3- carboxylate methyl ester derivative C15H22N2O5The synthetic method of S | 南京大学连云港高新技术研究院 | 2018-12-21 | — | — | CN | claimed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| CN-102797043-A | Medicinal molecular fragment library and construction method thereof | CBB NETWORK CO LTD | 2012-11-28 | — | — | CN | claimed |
| CN-101909631-B | Process for making thienopyrimidine compounds | GENENTECH INC | 2012-09-12 | — | — | CN | claimed |
| CN-101909631-A | Process for making thienopyrimidine compounds | GENENTECH INC | 2010-12-08 | — | — | CN | claimed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | KMT2A 2454/4885ALDH1A1 1766/4885MEN1 1664/4885 |
| US-20230391791-A1 | Compositions And Methods For Oral Delivery Of Crystalline PRX-3140 Potassium Salt | KCNK10, CHRNA10, PRNP | KMT2A 2273/4885ALDH1A1 4092/4885MEN1 3427/4885 |
| US-11993609-B2 | Compositions and methods for oral delivery of crystalline PRX-3140 potassium salt | KCNK10, CHRNA10, PRNP | KMT2A 2273/4885ALDH1A1 4092/4885MEN1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.